FDA Advisory Panel Rejects Acadia’s Antipsychotic for Alzheimer’s – The Epoch Times

Related Articles:

• Your message was heard: Parkinson’s Awareness Month 2021 summary May 13, 2021 There were two focuses of this year’s Parkinson’s Awareness Month. The first was on combatting misconceptions and celebrating resilience with the No Matter What messages you saw on social media. The second was on making sure that the issues that matter to you, including timely diagnosis and access to care, were covered in national and local media across the country.…
• How Often Does the FDA Disagree With Its Advisory Committees’ Recommendations? July 25, 2019 According to the findings of a recent review, the Food and Drug Administration (FDA) rarely disagrees with recommendations made by its advisory committees. To better understand the factors that contribute to disagreement between the FDA and its advisory committees, the authors of the review examined meeting documents (from 2008-2015) that discussed medical product safety and/or efficacy. Specifically, they looked at the…
• FDA Rejects Pimavanserin sNDA for Dementia-Related Psychosis April 8, 2021 The Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Acadia Pharmaceuticals regarding the supplemental New Drug Application (sNDA) for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis. The sNDA submission was supported by data from the pivotal phase 3 HARMONY study (ClinicalTrials.gov: NCT03325556) that compared the efficacy and safety of pimavanserin,…
• Benefits of Acadia’s Nuplazid Outweigh Risks for Parkinson’s Psychosis Patients, FDA Reports September 24, 2018 Nearly half a year after news reports surfaced about deaths allegedly linked to Nuplazid (pimavanserin) — a therapy for Parkinson’s patients with disease-related psychosis — the U.S. Food and Drug Administration says it could not find any new or unexpected safety concerns with the controversial treatment. The agency said in a Sept. 20 press release that “after a thorough review, the FDA’s…
• COVID-19 and Parkinson’s February 12, 2021 Parkinson Canada is dedicated to the health and wellbeing of all people living with Parkinson’s. We continue to closely monitor information on the COVID-19 pandemic provided by the Public Health Agency of Canada and other public health authorities. What we know today is that the distribution of vaccines is rolling out across Canada in a phased approach that prioritizes access…
• FDA Continuing to Monitor Nuplazid Use, Agency Says in Response to Controversial CNN Report April 16, 2018 The U.S. Food and Drug Administration is keeping close watch on the use of Nuplazid (pimavanserin) by Parkinson’s patients with disease-related psychosis, but at present sees no reasons to change the existing warnings placed on the medication — sold by Acadia Pharmaceuticals — when first approved. The FDA stated its position, given in response to a recent CNN report on patient…
• Meet the Newest Davis Phinney Foundation Leaders in Parkinson’s December 8, 2020 We are delighted to announce the creation of The Davis Phinney Foundation Inclusion, Diversity, Equity, and Access (IDEA) Advisory Board. This team of renowned healthcare providers and leaders in the fields of equity and inclusion will play an integral role in our work to better understand and change deeply rooted inequities in healthcare that black, brown, and indigenous communities; LGBTQ+;…
• Nuplazid ‘Significantly’ Slows Relapses in Dementia-Related Psychosis, Phase 3 Trial Shows October 7, 2019 Interim results from the ongoing Phase 3 HARMONY study show that treatment with Nuplazid (pimavanserin) significantly delays time to a psychosis relapse in patients with dementia-related disorders, such as Parkinson’s and Alzheimer’s disease. Evaluation by an independent data monitoring committee recommended an early stop to this placebo-controlled trial based on the treatment’s “robust” efficacy, Acadia Pharmaceuticals — Nuplazid’s manufacturer — announced in a…
• New Phase 3 Trial to Test Nuplazid for Parkinson’s Psychosis in Array of Dementia Patients October 5, 2017 Acadia Pharmaceuticals is starting a new Phase 3 clinical trial testing the efficacy of pimavanserin to treat the hallucinations and delusions associated with dementia-related psychosis in a broad array of patients with Parkinson’s, Alzheimer’s, and many other dementias. Pimavanserin, under the brand name Nuplazid, was approved by the U.S. Food and Drug Administration (FDA) to treat dementia-related psychosis in Parkinson’s patients in 2016. This trial, and the Breakthrough…
• ‘Inappropriate’ Antipsychotics to Treat Depression in Elderly Parkinson’s Patients Linked to Pneumonia Risk November 6, 2019 Inappropriate antipsychotic medications — those approved for ills like schizophrenia but used to treat depression — given to elderly people with Parkinson’s disease increase their risk of pneumonia, a study suggests. The study, “Risk of pneumonia associated with atypical antipsychotic use in nursing home residents with Parkinson’s disease,” was published in the Journal of Psychiatric Research. Certain antipsychotic medications can be prescribed…
• Acadia Supports Events to Mark Parkinson’s Disease Awareness Month in U.S. April 16, 2019 Acadia Pharmaceuticals is marking Parkinson’s Awareness Month by supporting a host of events and activities in April throughout the U.S. Although some events have occurred, several are annual events needing participation. “We encourage patients and their families to attend an event, which includes important resources to help them navigate their unique journey with Parkinson’s,” said Steve Davis, Acadia’s CEO, in…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia? June 25, 2021 BMC Neurol. 2021 Jun 24;21(1):240. doi: 10.1186/s12883-021-02265-x.ABSTRACTBACKGROUND: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1)…
• Parkinson’s Foundation Recruits 5 New Members to Its Advisory Council June 18, 2018 The People with Parkinson’s Advisory Council of the Parkinson’s Foundation has five new members. The council is made of people living with Parkinson’s disease and their caregiver partners who contribute with their personal perspectives and experience to ensure that all the foundation’s programs and services are based on real-world needs and evidence. “One of the fundamental ways the Parkinson’s Foundation serves its…
• Nuplazid Review Endorses Treatment, But Pinpoints Additional Study Needs January 9, 2018 Even though 60 percent of Parkinson’s Disease patients develop psychotic symptoms, it was only in 2016 that a treatment for the condition was approved. Nuplazid (pimavanserin) employs an entirely different mechanism to control psychotic symptoms compared to the bulk of antipsychotic medications on the market. The review, “Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis,” took a look at…
• Recon: PTAB Rejects Bid to Challenge Celgene's Revlimid Patent - Regulatory Focus March 14, 2019 Recon: PTAB Rejects Bid to Challenge Celgene's Revlimid Patent  Regulatory FocusWelcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. US court rejects Alvogen's patent challenge for ...
• FDA Rejects Nuplazid for Alzheimer's, Other Dementia-related Psychosis - Alzheimer's News Today April 5, 2021 FDA Rejects Nuplazid for Alzheimer's, Other Dementia-related Psychosis  Alzheimer's News Today
• Coming Soon…the Rune Labs’ Patient Advisory Board February 10, 2022 Back in the good ol’ pre-covid days of 2018, I went to my neurologist, Dr. Alfonso Fasano, with an idea about speaking to the doctors at my clinic about the journey I’d been on as a patient advocate. He loved it and arranged a talk at the Toronto Western Hospital (TWH) for the entire Movement Disorder Clinic (MDC). Among those…